Cell Therapeutics, BioTime, Human Genome Sciences Examined On The One-Year Chart

By Rick King - Cell Therapeutics (NASDAQ:CTIC), Biotime (AMEX:BTIM), Human Genome Sciences (NASDAQ:HGSI) Continues Year-Long Ascent - Shares of Cell Therapeutics Inc (NASDAQ:CTIC) resumed their downward trend yesterday and closed at just under a dollar as concerns continued regarding executive bonuses and wavering investor confidence surrounding review of their New Drug Application for Pixantrone by the FDA's Oncologic Drugs Advisory Committee. The application is for pixantrone to treat relapsed, refractory aggressive non-Hodgkin's lymphoma and the new hard date for the review is now March 22nd. Final decision by the FDA for approval or denial is expected by April 23rd.